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 1 
Stage 2 Abstract 
 
Hard-to-heal leg ulcers are a major cause of morbidity in the elderly 
population. Despite improvements in wound care, some wounds will not heal 
and they present a significant challenge for patients and healthcare providers. 
A multi-centre cohort study was conducted to evaluate effectiveness and 
safety of a synthetic, extracellular matrix protein as an adjunct to standard 
care in the treatment of hard-to-heal venous or mixed leg ulcers. Primary 
effectiveness criteria were (1) reduction in wound size evaluated by 
percentage change in wound area and (2) healing assessed by number of 
patients healed by end of the 12 week study. Pain reduction was assessed as 
a secondary effectiveness criteria using VAS. A total of 45 patients completed 
the Study and no difference was observed between cohorts for treatment 
frequency. Healing was achieved in 35.6% and wound size decreased in 
93.3% of patients. Median wound area percentage reduction was 70.8%.  
Over 50% of patients reported pain on first visit and 87.0% of these reported 
no pain at end of Study. Median time to first reporting no pain was 14 days 
after treatment initiation. The authors consider the extracellular synthetic 
matrix protein an effective and safe adjunct to standard care in the treatment 
of hard-to-heal leg ulcers. 
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INTRODUCTION 
 
All health care professionals treating wounds inevitably face the challenge of 
treating wounds recalcitrant to standard care and this can be a source of 
significant frustration for both patients and clinicians. Hard-to-heal venous leg 
ulcers, or ulcers of a duration longer than four weeks and which fail to respond 
to standard of care (moist wound healing and compression), are a major 
cause of morbidity in the elderly population1-6. The annual number of patients 
with hard-to-heal wounds is conservatively estimated to be at 1% of the 
general population and the burden of hard-to-heal wounds, especially venous 
leg ulcers (VLUs), is expected to increase in ageing populations6-9. 
 
The failure of a hard-to-heal wound to close may be the result of a number of 
factors, including prolonged inflammation, inadequate fibroblast function, 
inadequate tissue oxygenation, excessive or uncontrolled protease activity, or 
a dysfunctional extracellular matrix (ECM)1,10,11. Varied systemic factors such 
as advanced age, malnutrition, diabetes and renal disease may also impair 
healing12.  In addition, pain has been shown to delay healing and pain-
induced stress has been suggested as an obstacle to wound healing13.  
 
Use of a systematic clinical approach is important when hard-to-heal wounds 
present since the healing process needs to be managed to convert a non-
healing wound to a healing wound. It is important first to evaluate and control 
those reasons for lack of healing progression related to chronic disease, and 
thereafter focus on the local condition of the wound itself14. One common 
Effectiveness of an novel acellular matrix in the treatment of hard-to-heal leg ulcers.  
Main document with references  
 3 
finding regardless of etiology is high levels of degradative proteases leading 
to a hostile wound environment and a dysfunctional wound ECM11,15,16.  
 
The ECM constitutes most of the dermis and is integral to wound healing as it 
provides sites for attachment of skin cells. Importantly, critical cellular 
functions such as proliferation and migration and survival of skin cells are all 
dependent on cell adhesion17,18. Hard-to-heal wounds overexpress proteases 
resulting in degradation of the ECM and growth factors, increased 
inflammatory response, reduced cell responsiveness and consequently 
delayed wound healing19. An impaired ECM interferes with the normal 
interaction between cells and the ECM and may delay or ultimately stop 
healing. Effective clinical treatment therefore requires repair and restoration of 
the ECM. 
 
The importance of the ECM for wound healing is well recognised and a 
number of ECM replacement products aimed at restoring the cellular milieu in 
hard-to-heal wounds have recently been made commercially available to 
health care providers20. These have been derived from allogeneic or 
xenogenic sources and have been designed in various forms, including 
collagen-based scaffolds, decellularised dermis, small intestinal submucosa 
and flowable ECM replacement proteins20-23.  
 
The aim of treating hard-to-heal wounds with an ECM replacement is to 
change the non-healing status of the wound by providing a temporary 
biomimetic ECM replacement that when placed in the wound bed offers a 
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temporary support to which cells can attach, migrate and proliferate in an 
organized manner, and which thus may lead to tissue regeneration and 
ultimately wound closure1, 24.  
 
The first international consensus on acellular matrices was recently published 
to help clinicians evaluate how to use these products in a variety of wound 
healing situations. Ideal products should achieve wound closure or reduce 
ulcer area, have no host immune response, reduce pain and lower 
complication rates19. Since wounds require a functional matrix in order to 
heal, acellular matrices are likely to be a clinically relevant adjunct to standard 
of care in the treatment of all hard-to-heal wounds.  Therefore, biomimetic 
scaffolds should be easy to use and compatible with commonly used non-
adherent, semi-occlusive wound dressings that promote moist healing, as well 
as with compression therapy and pressure offloading. 
 
A, synthetic, biomimetic, acellular matrix has been developed as an ECM 
replacement.  This synthetic ECM protein comprises portions of Vitronectin 
and IGF-I (insulin-like growth factor-1) and is intended for the treatment of 
hard-to-heal ulcers, primarily leg ulcers. The pre-clinical work providing 
evidence that this synthetic matrix protein has the ability to function as an 
acellular scaffold for wound healing purposes has been reported in this 
Journal by Shooter et al. (2013) 25. The primary objective of the study reported 
in this paper was the evaluation of the effectiveness and safety of this 
synthetic ECM protein.  
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METHODS 
 
Study Design and Main Inclusion/Exclusion Criteria 
A prospective, multicenter, cohort study was conducted in four centres in the 
United Kingdom (UK) and Australia. The investigators were chosen for their 
expertise in conducting wound studies. The main inclusion criteria for the 
Study were: (1) presence of a hard-to-heal leg ulcer; (2) grade C6 venous 
disease (open ulcer) according to CEAP (Clinical – Etiology – Anatomy – 
Pathophysiology) classification26; (3) patient age  18 years; (4) ulcer surface 
area ≥ 2 cm2 and ≤ 30 cm2 and the largest length < 10 cm; and (5) an ankle 
brachial pressure index  0.7 to exclude patients not suitable for graduated 
compression therapy27, 28. The main exclusion criteria were: (1) Patients who 
had not received standard compression therapy at time of recruitment for 4 
weeks; (2) presence of clinical infection; (3) poorly controlled diabetes (HbA1c 
 12%); (4) treatment with corticosteroids, phlebotropic drugs, drugs with a 
vasorelaxing effect, antimicrobials or antiseptics; (5) inability to give informed 
consent; and (6) participation in any other wound research trials in the 
previous month.   
 
To mitigate the potential for treatment effects, all patients were maintained on 
wound dressings and compression bandaging in accordance with local 
practices. Hence, the only change introduced to a patient’s treatment regime 
was the addition of treatment with the investigational product. 
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Ethical Considerations 
This Study was conducted in accordance with the ethical guidelines of the 
Declaration of Helsinki, ICH Good Clinical Practice Guidelines and BS EN ISO 
14155:2009 regarding clinical investigations of medical devices for human 
patients. Prior to recruiting patients, approval was obtained from the 
Medicines and Healthcare products Regulatory Agency (MHRA) in the UK 
and the Therapeutics Goods Administration (TGA) in Australia, as well as the 
local ethics committees for all the Study sites. 
 
Written informed consent was obtained from all patients and Study records 
were de-identified for confidentiality. Patients were free to withdraw from the 
Study at any time without prejudice to their subsequent treatment. 
 
 
Study Cohorts 
Patients were allocated to one of two cohorts: C1 to receive treatment with the 
investigational product once per week, and C2 to receive treatment with the 
investigational product twice per week. Each site allocated consecutively 
numbered patients to C1 and C2 in turn, starting with the first patient being 
allocated to C1. 
 
 
Treatment Protocol and Follow-Up 
Patients were treated with the investigational product in conjunction with 
standard wound care for 12 weeks, or until completely healed (defined as 
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100% epithelialisation). Standard wound care included wound cleansing with 
saline or water and gentle removal of sloughy or necrotic tissue. Sharp 
debridement was not used.  The synthetic ECM protein was applied topically 
to the wound bed according to the manufacturer’s Instructions for Use (Figure 
1) and covered by a non-adherent dressing followed by compression. 
Dressings were changed and the treatment procedure repeated once per 
week for C1 and twice per week for C2, at which time points the safety and 
effectiveness assessments were also performed. Duration of treatment and 
follow-up was 12 weeks or healing, whichever came first. 
 
 
Endpoints 
Effectiveness 
Healing was assessed by the number and percentage of patients healed 
(i.e.100% epithelialised) by the end of the 12-week study period. Reduction in 
wound size was evaluated by the percentage change in wound area using 
computer planimetry assessments of ulcer size from wound tracings on 
gradated acetate sheets and by digital photography. Tracings and 
photography were carried out at entry to the Study and at each planned study 
visit.  
 
All patients were asked to evaluate their level of pain using a Visual Analogue 
Scale (VAS), a validated instrument for measuring the severity of pain using a 
100 mm scale29. Patients were presented with a 100 mm line where the 0 mm 
mark indicated no pain and 100 mm indicated the worst pain imaginable. To 
Effectiveness of an novel acellular matrix in the treatment of hard-to-heal leg ulcers.  
Main document with references  
 8 
ensure the robustness of this subjective endpoint, pain was recorded on the 
case report form by the patient30. The patient completed the assessment of 
overall ulcer pain in the week preceding the visit at baseline and at each 
subsequent follow up assessment the patient assessed the overall ulcer pain 
since his or her previous visit. 
 
Each patient’s pain measurement was read centrally using a 100 mm ruler 
and was then converted to a score out of 100. 
 
The following interpretation of the VAS scores was used: 0-4 mm = no pain; 
5-44 mm = mild pain; 45-74 mm = moderate pain; and 75-100 mm = severe 
pain, with a 33% reduction in pain representing a clinically meaningful pain 
reduction31. 
 
 
Safety 
Patients were carefully monitored throughout the Study for Adverse Events 
(AEs). An AE was defined as any unfavourable or unintended sign or 
symptom, or disease temporally associated with the use of the Study product 
and/or cover dressing. At each follow-up visit, patients were asked if they had 
experienced any AEs since their last visit and spontaneously reported AEs 
were also captured. Details recorded included description, seriousness and 
relationship to the study product and/or cover dressing. The investigators 
determined the relationship using the following categories: none, improbable, 
possible, probable or definite.  
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An AE was classified as a Serious Adverse Event (SAE) if it led to death or a 
serious deterioration in health of a patient that resulted in a life threatening 
illness or injury, resulted in permanent impairment of body structure or a body 
function, required inpatient hospitalisation or prolongation of hospitalisation, or 
resulted in medical or surgical intervention to prevent permanent impairment 
to a body structure or body function. 
 
 
Statistical Methods 
In this observational, non-comparative Study a sample size of 58 patients was 
based on feasibility and chosen to account for a dropout rate of approximately 
30% providing a minimum of 40 evaluable patients completing the Study.  
 
Evaluation of the effectiveness and safety endpoints was descriptive in 
nature. Healing was assessed by the number and percentage of patients 
healed by the end of the Study. Reduction in wound size was evaluated by 
percentage change in wound area from baseline and calculated for each 
assessment (the difference between baseline – post-baseline assessment 
value divided by the baseline value and the result converted to a 
percentage).  Time to first occurrence of at least 50%, 75% reduction and to 
healing were presented graphically using Kaplan-Meier product limit survival 
estimates.   
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Change in pain was evaluated by percentage change in pain from baseline 
and was calculated for each assessment (the difference between baseline – 
post-baseline assessment value divided by the baseline value and the result 
converted to a percentage). The time to first occurrence of a clinically 
meaningful pain reduction (i.e. at least 33%) and to no pain were presented 
graphically using Kaplan-Meier product limit survival estimates. 
 
Safety was analysed using descriptive summaries of overall frequency and 
incidence of all AEs and AEs by relatedness to the study product and/or cover 
dressing. 
 
Patients who were treated with the synthetic ECM protein comprised the 
intention-to-treat population, or in other words the Full Analysis Set (FAS). 
Patients who completed the Study (i.e. 12 weeks or complete healing) 
comprised the per protocol or the Completers Analysis Set (CAS) population.  
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RESULTS 
 
Demographics 
Fifty-four patients with venous insufficiency or mixed leg ulcers were recruited. 
Following allocation to cohorts, one patient no longer satisfied the inclusion 
criteria and was withdrawn prior to treatment, while eight patients did not 
complete the Study for various reasons. This resulted in 45 evaluable patients 
(CAS) and therefore the target of 40 evaluable patients was met. The flow of 
patients throughout the Study and reasons for non-completion are shown in 
Figure 2.  
 
The mean patient age was 74.2 years. The mean ulcer duration was 37.1 
months and the mean ulcer size was 7.36 cm2 at baseline. Three (6.7%) 
patients had an ABPI of <0.8 and 20/45 (44.4%) patients had an ABPI > 1.2 
indicating a mixed arterial/venous ulcer etiology in 23/45 (51.1%) of the 
patients 27,32. Importantly however, it was determined by the responsible 
clinicians that compression was safe and beneficial to use in the treatment of 
these mixed ulcers. The demographics and baseline wound characteristics for 
both the FAS and the CAS populations are shown in Table 1. 
 
 
Dressings Used in the Study 
The compatibility of the synthetic ECM protein with dressings and 
compression bandages commonly used in the provision of standard leg ulcer 
care is demonstrated by the great variety of dressings and compression 
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systems successfully employed with the synthetic ECM protein in the Study 
(Table 2).  
 
 
Cohort Analysis 
Cohort analysis showed that the two Study cohorts were similar and no 
statistical difference or clinically meaningful difference in effectiveness 
between cohorts was observed. 
 
 
Healing and Wound Area Reduction 
The incidence of complete healing was 16/45 patients i.e. 35.6% (Figure 3), 
and the median wound area percentage reduction was 70.8% (Table 3). 
 
In a total of 30/45 (66.7%) patients significant improvement, i.e. >50% wound 
area reduction, was observed and 42/45 patients (93.3%) improved i.e. had 
over 20% wound area reduction (Figure 3). Time to healing/partial healing is 
shown in Figure 4. 
 
No formal statistical subgroup analysis was performed; however, as expected, 
there was a trend for healing outcome to be associated with smaller wound 
size at baseline and with shorter durations of wounds at baseline.  Amongst 
healed patients, the majority of wounds were < 3 cm2. More than 40% of 
those who healed within this 12 week Study (7/16) presented with a wound 
duration at baseline of six months or less, while amongst non-healed patients 
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approximately 28% (8/29) were in this category. Of the healed patients, 43.8% 
patients were < 65 years and of the non-healed patients 4/29 (13.8%) were < 
65 years (Tables 4a, 4b, 4c). 
 
Examples of outcomes when adding the synthetic ECM protein as an adjunct 
treatment are provided in Figures 5a, 5b, 6a and 6b.  
 
A small (2.29 cm2), recurrent venous ulcer had been present for 3 months on 
the left leg, medial calf area, in this 77-year-old woman with no response to 
standard care (Figure 5a). Following 6 weeks of standard care and the 
synthetic ECM protein, healing was achieved (Figure 5b).  
 
In a woman, aged 78 years, a venous ulcer (15.4cm2 in size) had been 
present for 5 years on the right leg in the medial gaiter area (Figure 6a). The 
ulcer, which had not responded to standard care alone, healed within 7 weeks 
of bi-weekly treatment with standard care and the synthetic ECM protein 
(Figure 6b). 
 
 
Pain 
At baseline 23/45 (51.1%) patients presented with pain. Of these 6 had 
severe pain, 5 had moderate pain, and 12 had mild pain. All patients reporting 
severe pain at baseline reported no pain at final visit. A clinically meaningful 
(33%) pain reduction was experienced by all patients and the median time to 
achieve such pain reduction was 7 days after treatment with the Study 
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product was initiated. Of the 23 patients with pain, 20/23 (87.0%) reported 
reduction to no pain at end of the Study and the median time to the patients’ 
first report of no pain was 14 days after treatment with the Study product was 
initiated (Figure 7).  
 
Safety 
A variety of AEs were reported during the Study (Table 5). Of a total of 
105 AEs, 48.6% (51/105) were considered associated with the Study wound 
(Table 6). However, no AEs were considered definitely or probably related to 
the synthetic ECM protein. 
Thirteen of the Study wound associated (13/51 [25.5%]) AEs were considered 
possibly related to the synthetic ECM protein. These were comprised of five 
AEs of hypergranulation, two AEs of maceration, two AEs of bleeding wound 
bed, and one AE each of increase in wound size, pain associated with Study 
wound, erythema with excoriation of surrounding skin, and itching around the 
wound. Three AEs (3/13 [23.1%]) were considered moderate in severity 
(increase in wound size, pain, erythema with excoriation of skin) and all others 
(10/13 [76.9%]) were considered mild in severity. 
The three most frequently reported AEs were Study wound associated AEs 
and included maceration (19/51 [37.3%]), infection (8/51 [15.7%]) and 
hypergranulation (6/51 [11.8%]). Importantly, none of the wound associated 
AEs were classified as severe by the investigators. The AEs reported in the 
Study were all the type of adverse events which are commonly encountered in 
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the treatment of patients with leg ulcers. There were 23 cover dressing related 
AEs in total, of which 16 were Study wound associated (Table 6).  
A total of four wound associated AEs led to withdrawal from the Study. In 
three of the cases the reason was that the protocol stipulated withdrawal due 
to wound infection, and in one case the reason was due to increase in ulcer 
size. All four were classified as moderate in terms of severity. 
There were two deaths reported in the Study. Given the age and 
comorbidities of the Study participants this was not unexpected and 
importantly neither of them was Study wound associated or considered 
related to the synthetic ECM protein. 
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DISCUSSION 
This Study included a number of subjective and objective endpoints providing 
a comprehensive evaluation of the effectiveness and safety of a synthetic 
ECM protein in the treatment of hard-to-heal leg ulcers.   
 
There were no SAEs or severe AEs where causality was definitely, or even 
possibly, attributable to the synthetic ECM protein thereby further illustrating 
the low risk profile of this synthetic product. Safety data are surprisingly often 
missing in published wound care studies. However, based on the few 
publications providing such data we conclude that the AE profile of the 
patients in this Study is similar to the safety data published for patients with 
hard-to-heal leg ulcers,33,34,35 and that treatment with the synthetic ECM 
protein is well tolerated by this particular patient population.  
 
Leg ulcers are associated with disabling pain and chronicity36, have a major 
impact on quality of life37 and for patients with previously unsuccessful wound 
treatment, the condition can persist for years. ECM treatment of hard-to-heal 
wounds has been associated with greater pain reduction compared to control 
treatments35, 38-41, albeit that the instruments for measuring pain greatly vary. 
Nevertheless, the important pain reduction following treatment with the 
synthetic ECM protein compares favourably with that published for an animal-
derived protein, amelogenin (Xelma Mölnlycke) in a reported 12 week study 
where pain reduction was significantly greater in the amelogenin treatment 
group compared to the control group35,40. Moreover, in this synthetic ECM 
protein Study all patients with severe pain at baseline reported no pain at the 
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final follow-up visit, and 87% of all patients with pain reported no pain in a 
median time of two weeks after baseline treatment. 
 
It has been concluded that amelogenin, in conjunction with compression, is 
beneficial in the treatment of hard-to-heal venous leg ulcers. The healing 
results of the present study also compare favourably with the clinical 
experience of Vowden et al. (2007)35 and Romanelli et al. (2008)40 using 
weekly applications of amelogenin in a similar 12-week study to treat patients 
with hard-to-heal, mixed or venous ulcers35,40. Romanelli et al. (2008)40 
reported that 9/42 (21%) of patients treated with amelogenin were fully healed 
at 24 weeks40, while in this Study, 16/53 (30%) of patients treated with the 
synthetic matrix protein were fully healed already at 12 weeks (N=53).  
Furthermore, given the percentage wound area reduction achieved at 12 
weeks in this Study it could be reasonably expected that an even greater 
percentage would have been fully healed at 24 weeks42. 
 
As previously noted, hard-to-heal wounds are a massive burden for patients 
and a significant challenge for healthcare providers as well as the healthcare 
system. Some 20–30% of leg ulcers do not respond to compression therapy 
and the use of additional treatment options to improve outcomes may be 
needed24. In this 12 week Study the use of the synthetic ECM protein as an 
adjunct to standard care resulted in the per protocol population in an overall 
total healing rate of 35.6% for hard-to-heal ulcers (median duration at Study 
entry 10 months). It may therefore be hypothesized that early referral and 
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addition of the ECM protein as an adjunct to standard of care may bring about 
an important improvement in patient outcomes.  
 
In addition, from an effectiveness, and therefore health economics point of 
view, it is important that the timing of the use of an adjunct therapy be 
sensibly chosen43.  Kantor and Margolis (2000)3 demonstrated in a study 
aimed at helping health care providers decide when to use adjunct therapies 
in the treatment of wounds that the status of a wound following four weeks of 
treatment is a good predictor of final outcome.  In light of the results of this 
Study it would therefore follow that if there is no or poor response to standard 
care treatment alone after 4 weeks, patient suffering, use of resources and 
financial costs may be reduced by prompt addition of the synthetic ECM 
protein as an adjunct to standard care in order to improve outcomes. 
 
A potential limitation of the study is the relatively short duration. Nevertheless, 
the Study is a comprehensive evaluation of a total of 8.4 patient treatment 
years and the percentage wound area reduction achieved at 12 weeks in this 
Study provides a useful indicator of longer term further improved outcomes42. 
 
Conclusion 
This Study demonstrates the effectiveness of the synthetic ECM protein in the 
treatment of hard-to-heal mixed and venous leg ulcers as measured by 
healing or reduction in wound size. The high level of performance in healing, 
wound area reduction and important pain reduction, together with the robust 
safety profile, demonstrate the benefit of using the synthetic ECM protein as 
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an adjunct to standard care in the treatment of patients with hard-to-heal 
mixed or venous leg ulcers. Moreover, the results indicate an even greater 
benefit from an early use of this synthetic ECM protein when standard care 
alone does not provide results and suggest an important health economic 
benefit, especially in a community setting, from early referral and use.  
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TABLES 
 
 
 
Table 1  Patient demographic information 
 
Baseline data  FAS (n=53) 
  
Age (years) 
 
Wound duration 
(months) 
 
Wound area  
(cm
2
) 
Mean 74.0 33.4 7.38 
Max 100 360 32.9 
Min 49 1 1.8 
Median 75.0 10.0 4.5 
SD (+/-) 11.5 59.5 6.96 
Gender Males Females Total 
 29 (54.7%) 24 (45.3%) 53 
ABPI* <0.8 ≥ 0.8-≤ 1.2 >1.2 
 4 25 23 
 
Baseline data  
 
CAS (n=45) 
 
 
Age (years) 
 
Wound duration 
(months) 
 
Wound area  
(cm
2
) 
Mean 74.2 37.0 7.36 
Max 100 360 32.90 
Min 49 1 1.80 
Median 77.0 10.2 4.69 
SD (+/-) 11.8 63.8 6.92 
Gender Males Females Total 
 26 19 45 
ABPI* <0.8 ≥ 0.8-≤ 1.2 >1.2 
 3 21 20 
*missing data for 1 patient 
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Table 2 Range of cover dressings and compression systems used in the Study  
 
 
 
  
Cover Dressing/ 
Compression Type 
Used in > 5% of Treatments 
Number of Treatments (%) 
 
N = 713 
Number of Patients (%) 
 
N = 53 
Non-Adherent dressing;  
High Compression 
180 (25.2%) 
 
25 (47.2%) 
Antimicrobial dressing; 
High Compression 
132 (18.5%) 13 (24.5%) 
Absorbent dressing; 
Short Stretch 
102 (14.3%)  7 (13.2%) 
Tubular paste bandage; 
Short Stretch 
 61 ( 8.6%)  4 ( 7.5%) 
Absorbent dressing; 
High Compression 
 37 ( 5.2%)  4 ( 7.5%) 
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Table 3  Healing and percentage wound area reduction at final visit 
 
Total CAS (n=45)  
 
Completely healed n (%) 
        
16 (35.6%) 
 
% Reduction in wound area at last assessment 
Mean 54.05 
Max   100.00 
Min -120.00* 
Median 70.80 
SD 57.28 
*a negative value indicates a percentage increase in wound area compared with Study entry 
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Table 4a Wound size and final study outcome 
Wound size at baseline Healed patients  
(n=16) 
Non-healed patients 
(n=29) 
All patients 
(n=45) 
< 3 cm
2 
10  62.5%  4  13.8%  14  31.1%  
> 3 to ≤ 6 cm
2
 3  18.8%  10  34.5%  13  28.9%  
> 6 to ≤ 12 cm
2
 2  12.5%  8  27.6%  10  22.2%  
> 12 cm
2
 1  6.3%  7  24.1%  8  17.8%  
Total  16  100.0%  29  100.0%  45  100.0%  
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Table 4b Wound duration and final study outcome 
Wound duration Healed patients 
(n=16) 
Non-healed patients 
(n=29) 
All patients 
(n=45) 
≤ 6M  7  43.8% 8  27.6%  15 33.3% 
> 6M to ≤ 12M  5  31.3%  5  17.2%  10 22.2% 
>12M to ≤ 24M  0    0.0%  3  10.3%  3 6.7% 
> 24M  4  25.0%  13  44.8%  17 37.8% 
Total  16 100.0%  29  100.0%  45 100.0% 
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Table 4c Age group and final study outcome 
Age group at baseline Healed patients 
(n=16) 
Non-healed patients 
(n=29) 
All patients 
(n=45) 
< 65 years
 
7 43.8% 4 13.8% 11 24.4% 
> 65 to ≤ 75 years 3 18.8% 8 27.6% 11 24.4% 
> 75 to ≤ 85 years 4 25.0% 12 41.4% 16 35.6% 
> 85 years 2 12.5% 5 17.2% 7 15.6% 
Total  16 100.0% 29 100.0% 45 100.0% 
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Table 5  Adverse events reported in the study 
 
AEs considered to be study wound associated  Other AEs 
Bleeding wound bed 
Eczema 
Folliculitis 
Hypergranulation tissue  
Increased exudate 
Maceration to surrounding skin causing new ulcer 
New ulcer 
New wound 
Oedema  
Overgranulating tissue 
Pain 
Superficial maceration 
Unhealthy tissue 
Worsening itch 
Wound infection 
Atrial fibrillation 
Chest infection 
Chesty cough  
Cold  
Conjunctivitis  
Death 
Dizziness 
Furring of tongue  
Haemorrhage behind left eye due to 
hypertension 
Hay fever 
Hives 
Nausea 
Rash 
Superficial foot cellulitis  
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Table 6 Relationship of wound associated AEs to the synthetic ECM protein and/or to the 
cover dressing  
 
  
AEs related to the synthetic ECM 
protein 
AEs related to cover dressing 
None 7 13.7% 19 37.3% 
Improbable 31 60.8% 16 31.4% 
Possible 13 25.5% 13 25.5% 
Probable 0 0.0% 2 3.9% 
Definite 0 0.0% 1 2.0% 
Total 51 100.0% 51 100.1*% 
* Percentage is not equal to 100-0% due to rounding 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5a 
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Figure 5b 
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Figure 6a 
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Figure 6b 
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Figure 7 
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